# Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma

> **NCT00752063** · PHASE2 · UNKNOWN · sponsor: **The University of Hong Kong** · enrollment: 52 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma
- Metastatic Hepatocellular Carcinoma

## Interventions

- **DRUG:** Sorafenib with Capecitabine and Oxaliplatin

## Key facts

- **NCT ID:** NCT00752063
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-09
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2008-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00752063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00752063, "Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00752063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*